Guide on extending expiration dates of marketed drugs in response to drug shortages (GUI-0500)
Version:1
Date issued: October 7, 2026
Disclaimer: This document does not constitute legislation. If there is any inconsistency or conflict between the legislation and this document, the legislation takes precedence. This document is an administrative document intended to help the regulated party comply with the legislation and the applicable administrative policies.
On this page
- Overview
- Understanding the framework
- Submit a proposal
- Compliance and enforcement
- Reporting adverse reactions related to drugs with extended expiration dates
- Definitions
- Resources
- Contact us
Overview
Introduction
Health Canada helps people in Canada maintain and improve their health. This is done, in part, through our commitment and actions to help address and mitigate the risk of harm to human health caused by drug shortages. Our goal is to help ensure that people in Canada have access to the drugs they need when they need them.
Under sections C.10.014 to C.10.021 of the Food and Drug Regulations (FDR), the expiration date of specified drug lots or batches may be extended as an exceptional measure to help mitigate the impact of a shortage.
Note: The terms "lot" and "batch" are used interchangeably. For ease of reference, we use "batch" in this guidance document.
Purpose
This guidance document will help market authorization holders (MAHs) and drug establishment licence (DEL) holders understand how to comply with sections C.10.014 to C.10.021 of the FDR, including:
- definition of an extended expiration date
- the process to specify a drug product batch (that is, the specified lot or batch) on the List of Drugs with Extended Expiration Dates (Extended Expiration Date List)
- the conditions for adding and removing drug product batches from the Extended Expiration Date List
- the notification requirements for MAHs and DEL holders when a drug product is added to or removed from the Extended Expiration Date List
Scope and application
The provisions outlined in sections C.10.014 to C.10.021 of the FDR apply to any drug that:
- has a drug identification number (DIN)
- is in shortage or at risk of shortage that could present a risk of injury to human health
Note about guidance documents in general
Guidance documents provide assistance to industry on how to comply with governing statutes and regulations. They also provide guidance to Health Canada staff on how mandates and objectives should be met fairly, consistently and effectively.
Guidance documents are administrative, not legal, instruments. This means that Health Canada may consider alternative approaches to meeting the regulatory requirements that stakeholders may propose. However, to be acceptable, alternate approaches to the principles and practices described in this document must be supported by adequate justification. Stakeholders should discuss their proposals with us in advance so that we can determine whether the applicable statutory or regulatory requirements can be met.
In accordance with our regulatory authorities and mandate under the Food and Drugs Act, Health Canada may request other information or material, or define conditions not specifically described in this document. We may do so to help us adequately assess the safety, efficacy or quality of a therapeutic product. We are committed to ensuring that such requests are justifiable and decisions are clearly documented.
This document should be read in conjunction with the relevant sections of the regulations and other applicable guidance documents.
Understanding the expiry date extension framework
Sections C.10.014 to C.10.021 of the FDR allow the printed expiration date of specified drug product batches to be extended by adding it to the Extended Expiration Date List.
Specified drug product batches may be added to the list only if all of the following criteria are met:
- A drug identification number has been assigned to the drug under subsection C.01.014.2(1).
- There is a shortage or risk of shortage of the drug.
- A shortage of the drug, if it were to occur, could present a risk of injury to human health.
- Sufficient evidence has been provided demonstrating that the specified drug product batches will comply with its product specifications until at least the extended expiration date.
Given the purpose of this framework, if these 4 criteria are met, consideration would also be given to whether:
- extending the expiration date of the specified drug product batches will help to prevent or mitigate a shortage and
- the specified drug product batches can be used safely based on the evidence submitted.
Health Canada interprets risk of injury to human health due to a shortage as the likelihood that the interruption, lack or delay of treatment due to a shortage could cause harm to human health.
Certain drug shortages are considered more serious and are classified administratively as Tier 3 shortages. The Tier 3 designation can also be applied for drug discontinuations that are determined to significantly impact patient health. Tier 3 shortages are those that have the greatest potential impact on access to drugs and the health care system.
Learn more about these types of shortages and find a list of all drugs that have this status:
Health Canada reviews all available options to mitigate critical or Tier 3 shortages (for example, exceptional importation and sale, expiration date extension, collaborating with MAHs). An expiry date extension may be an effective means of mitigating a shortage in some situations.
For example, there may be instances where there is supply remaining at the MAH, wholesale, health care system or patient level that is nearing expiration. Extending the expiration date of a specified batch in such cases could increase the available supply for the drug.
Proposals for extending an expiration date on economic grounds will not be considered by Health Canada.
Submit a proposal
Proposal requirements
MAHs are expected to follow a process when submitting a proposal to add a specified drug batch to the list in response to a drug shortage or risk of drug shortage.
The completed proposal form should summarize key information, such as:
- a list of all drug product batches under consideration for an expiration date extension
- the current inventory levels of the specified batches at the MAH level with supplies available at the wholesale and health care system level, if known
- the approved shelf-life of the proposed drug product and the original printed expiration date for specified batches under consideration
- the proposed extended expiration date for all drug product batches under consideration
- evidence and justification to support the expiration date extension
- Refer to the next section for more information about the types of data required to support such an analysis.
- notification strategy to communicate the extended expiration date for specified batches
- other relevant information
The proposal form is available upon request at the following email address: drugshortages.prop.notif-penuriesmedicaments@hc-sc.gc.ca.
Evidence of quality for a specified drug batch past its printed expiration date
To extend the expiration date of a specified drug product batch beyond its printed expiration date, you must provide sufficient evidence and justification that the batch will comply with its specifications until at least the proposed extended expiration date. This means demonstrating that the batch can continue to be used safely and will comply with its specifications for the proposed extended expiration date period.
The following information should be included with the proposal as part of the justification:
- evidence that the specified drug product batch or batches will continue to comply with the product specifications, including all supporting stability data and discussion of the results, to help us verify the data analysis
- a summary and justification of the data analysis used to support the expiration date extension
- actual testing results presented in a manner to help us verify the analysis and conclusions
- an attestation that the stability data under consideration is from a Canadian-authorized drug product or equivalent
- An equivalent has the same formulation, manufacturing process and container closure system as the Canadian-authorized drug product.
- a summary of differences between the Canadian-authorized drug product and the drug product for which data is provided, in the absence of the attestation
- a reference and summary of any relevant out-of-specification stability testing results
- a risk assessment of any out-of-specification results that are identified
- additional testing commitments, if applicable
Consult the relevant Health Canada and International Council on Harmonisation (ICH) guidelines. These guidelines include recommendations to confirm the stability of drug products and the data required to establish and extend expiration dates. Examples of such documents include:
- Post-notice of compliance (NOC) changes – Quality guidance
- Guideline on preparation of DIN submissions
- ICH Q1A (R2) Stability testing of new drug substances and drug products – Scientific guideline
- ICH Q1E Evaluation of stability data – Scientific guideline
We encourage you to review existing accelerated and long-term stability data to determine if the data supports continued compliance of the drug product batch with specifications beyond the printed expiration date.
Examples of data that can be used to support extended expiration dates for a specific drug product batch include:
- extrapolation of data in accordance with the principles set out in the ICH Q1E guideline
- use of representative stability data (including data from other markets) if the data applies to Canadian products
- for example, equivalent to the Canadian formulation, manufacturing process and container closure system
- trending of stability results from the specific drug product batches under consideration if they have been enrolled in a stability program
Submitting a proposal
Health Canada encourages MAHs to discuss their justifications for extending an expiration date in response to a shortage before submitting a proposal.
Use the same email address to submit your completed proposal.
Email: drugshortages.prop.notif-penuriesmedicaments@hc-sc.gc.ca
Health Canada review
Health Canada will review each proposal, including the justification as necessary.
We may ask for clarification, more information or testing results and specify a timeframe for submitting this information.
There are 3 possible outcomes after our review:
- We accept the proposal with the proposed extended expiration date.
- We accept the proposal with a modified expiration date that's shorter than what you submitted in your proposal if the:
- shorter expiration date is expected to adequately mitigate the shortage
- further extensions may be granted if required
- data doesn't support the proposed expiration date extension
- additional testing to support a longer expiration date extension may be requested
- shorter expiration date is expected to adequately mitigate the shortage
- We reject the proposal and will not add the batch to the list if:
- the expiration date extension will not mitigate or prevent the shortage
- other options are being pursued or are in place that are expected to mitigate or prevent the shortage
- the data used to justify the expiration date extension is not adequate
We will review each proposal and notify you of our decision in a timely manner. The quality of the proposal, its complexity and the timelines required to mitigate the shortage may affect when we render our decision.
You should notify us immediately if the additional testing requested indicates a drug product batch does not meet acceptance criteria.
Adding a specified batch to the list
Once we accept a proposal, we will add the specified drug product batch to the Extended Expiration Date List. You will be notified by email before the batch is added to the list.
Once the batch is added, the drug can continue to be sold until the extended expiration date.
As set out in sections C.10.015 and C.10.016 of the FDR, the following information is posted publicly on the list:
- specified batch identifier of a drug (column 1)
- extended expiration date of the batch (column 2)
- drug product's brand and non-proprietary name
- original printed expiration date of the batch
- DIN assigned to the drug
- name of the manufacturer of the drug
- date when we added the batch to the list
We may shorten an extended expiration date for a specified drug product batch if the circumstances of a drug shortage change. This decision is made on a case-by-case basis and the MAH is informed in a timely manner.
If you wish to extend an expiration date further, you must submit a new proposal.
Notification requirements
When a specified drug product batch has been added to the list:
- MAHs must notify the DEL holders that they sold the batch to within 5 calendar days of the specified batch being added to the list (subsection C.10.020(1) of the FDR)
- DEL holders must notify any persons that they sold the batch to within 5 calendar days of being notified of the specified batch being added to the list (subsection C.10.020(2) of the FDR)
We may issue other communications if needed. We may also notify provincial and territorial partners, who will inform implicated parties such as hospitals and pharmacy regulatory authorities if needed.
Notification strategies are reviewed as part of the proposal.
MAHs are not required to re-label a batch with the extended expiration date.
Removing a batch from the list
We may remove a drug product batch from the Extended Expiration Date List under specific conditions, for example:
- incorrect or misleading information was provided in the proposal or any associated requests for information
- non-compliance with the FDR is identified
- for example, non-compliance with good manufacturing practices (GMPs)
- the drug or batch may pose safety, efficacy or quality risks
- for example, an issue resulting in a recall or stop sale, serious adverse reaction
- new testing data becomes available that negatively impacts the risk benefit assessment
We will notify the MAH when a specified batch is removed from the list as soon as possible, immediately after which:
- MAHs should notify the DEL holders or persons they sold the specified batch to
- DEL holders should notify the persons they sold the specified batch to
We may also issue other communications when a batch is removed from the list.
A specified drug product batch that is past its extended expiration date or is no longer on the list cannot be sold and should not be used.
Compliance and enforcement
Regulated parties are responsible for ensuring that they comply with the applicable requirements of the Food and Drugs Act and its regulations.
We conduct compliance and enforcement activities related to these regulatory requirements in accordance with our compliance and enforcement policy.
Compliance and enforcement policy for health products (POL-0001)
Reporting adverse reactions related to drugs on the list
Requirements for reporting adverse drug reactions apply to all specified drug product batches that have been added to the Extended Expiration Date List.
Learn more about reporting adverse drug reactions:
- Reporting adverse reactions to marketed health products
- Mandatory reporting of serious adverse drug reactions and medical device incidents by hospitals
Your report should include a note that the drug batch you suspect may have caused the adverse reaction has an extended expiration date. The extended expiration date and information on the drug batch should also be included.
Definitions
- Batch (or lot):
A specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or the amount produced in a fixed time interval. (ICH Harmonised Tripartite Guideline: Good manufacturing practice guide for active pharmaceutical ingredients (Q7))
The terms batch and lot are interchangeable. For ease of reference, batch is used to signify batch and lot.
- Drug establishment licence (DEL):
A licence issued to a person in Canada pursuant to Division 1A of the FDR to conduct licensable activities in a building that has been inspected and assessed as complying with the requirements of Divisions 2 to 4 of the FDR.
- Drug identification number (DIN):
-
An 8-digit numerical code assigned by Health Canada to each drug product marketed under the FDR.
A DIN uniquely identifies the following product characteristics:
- manufacturer
- brand name
- medicinal ingredient or medicinal ingredients
- strength of medicinal ingredient or medicinal ingredients
- pharmaceutical form
- route of administration
- Expiration date:
-
- in the case of a drug in dosage form, the earlier of the following dates, expressed at minimum as a year and month:
- the date up to and including which the drug maintains its labelled potency, purity and physical characteristics, and
- the date after which the manufacturer recommends that the drug not be used and
- in the case of an active ingredient, whichever of the following dates is applicable, expressed at minimum as a year and month:
- the retest date or
- the date after which the manufacturer recommends that the active ingredient not be used
(FDR, C.01.001)
- in the case of a drug in dosage form, the earlier of the following dates, expressed at minimum as a year and month:
- Extended expiration date:
For a specified lot batch or batch, the date set out in column 2 of the List of Drugs with Extended Expiration Dates.
- Inner label:
The label on or affixed to an immediate container of a food or drug. (FDR, A.01.010)
- List of Drugs with Extended Expiration Dates:
The List of Drugs with Extended Expiration Dates that is published by the Government of Canada on its website, as amended from time to time. (FDR, C.10.014)
- Lot number (or batch number):
Any combination of letters, figures or both by which any food or drug can be traced in manufacture and identified in distribution. (FDR, A.01.010)
- Manufacturer or distributor:
A person, including an association or partnership, who under their own name, or under a trade, design or word mark, trade name or other name, word or mark controlled by them, sells a food or drug. (FDR, A.01.010)
- Market authorization holder (MAH):
Refer to the definition for manufacturer or distributor.
- Outer label:
The label on or affixed to the outside of a package of a food or drug. (FDR, A.01.010)
- Package/label:
To put a drug in its immediate container or to affix the inner or outer label to the drug. (FDR, C.01A.001(1))
- Shortage:
For a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug is unable to meet the demand for the drug in Canada. (FDR, C.01.001(1))
- Specifications:
A detailed description of a drug, the raw material used in a drug or the packaging material for a drug and includes:
- a statement of all properties and qualities of the drug, raw material or packaging material that are relevant to the manufacture, packaging and use of the drug, including the identity, potency and purity of the drug, raw material or packaging material
- a detailed description of the methods used for testing and examining the drug, raw material or packaging material and
- a statement of tolerances for the properties and qualities of the drug, raw material or packaging material
(FDR, C.02.002)
- Specified lot or batch:
A lot or batch of a drug set out in column 1 of the List of Drugs with Extended Expiration Dates.
Resources
Legislation and regulations
Policies and guides
- Health Canada incorporation by reference policy
- Guide to reporting drug shortages and discontinuations (GUI-0120)
Web pages and associated documents
Contact us
For inquiries on the framework for extending an expiration date, email the Drug Shortages Unit at drug.shortages-penurie.de.medicament@hc-sc.gc.ca.
For general inquiries on drug shortages and discontinuations, email the Health Product Shortages Directorate at hpsdpdcorr-corrdgppsdp@hc-sc.gc.ca.